News & publications
Stay in the know about the science, events, and breakthroughs happening at Riboscience.
News
October 26, 2026 | PRESS RELEASE
Riboscience Presents Phase 1a/b Overall Survival Data for ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination Therapy in Advanced Solid Tumors and Late-Line CRC
MAY 30, 2025 | PRESS RELEASE
Riboscience Announces Successful Completion of Phase 1a Dose Escalation for RBS2418, a New Anti-Cancer Immunotherapy
October 19, 2026 | PRESS RELEASE
Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026
MAY 29, 2024 | PUBLICATION
Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab
OCTOBER 20, 2023 | PRESS RELEASE
Riboscience ESMO presentation highlights safety, PK, PD, and efficacy data from the first 19 patients of the ENPP1 inhibitor RBS2418 Phase 1 study
DECEMBER 7, 2022 | PRESS RELEASE
Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation
JUNE 20, 2022 | PRESS RELEASE
First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer